Lundbeck presents Phase Ib data for Lu AF28996 in Parkinson's

H Lundbeck A/S presented Phase Ib data for Lu AF28996 in advanced Parkinson's disease, showing it increases good on-time, reduces off-time and dyskinesia severity. A Phase II trial for the drug is now underway.